Luo et al. (29) have demonstrated that a switch in EZH2 function from histone-methyltransferase to non-histone methyltransferase led to methylation of STAT3 and promoted prostate cancer neuroendocrine differentiation. Here, PRDM9 is linked to prostate cancer.